Arvinas ARVN 深 滬
等待開盤 11-26 09:30:00 美东时间
12.12
+0.350
+2.97%
華盛通- 最 高12.21
- 今 開11.76
- 成交量 124.05万股
- 最 低 11.5931
- 昨 收 11.77
- 總市值 8.90亿
- 52周最高 26.78
- 市盈率 靜 --
- 換手率 1.69%
- 52周最低 5.90
- 委 比 -96.43%
- 總股本 7341.76万
- 歷史最高 108.465
- 量 比 0.24
- 振 幅 5.24%
- 歷史最低 5.90
- 每 手 1
- 風險率 5.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | 嘉楠科技飙升20%，Q3挖矿收入激增241%；Diginex涨超19%，公司与EVIDENT达成战略合作
嘉楠科技飙升20%，Q3营收破1.5亿美元，挖矿收入激增241%；Diginex涨超19%，公司与EVIDENT达成战略合作>>
11-19 16:54
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Olema Pharmaceuticals (NASDAQ:OLMA) stock increased by 137.7% to $20.2...
11-19 01:06
Annovis Bio Stock Jumps As New Data Shows Buntanetap Halts Cognitive Decline In Parkinson's Patients
Annovis Bio rises after Phase 3 data show buntanetap halted decline in Parkinson's patients, with results in those with amyloid co-pathology.
11-18 02:07
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
11-07 10:14
Barclays Maintains Overweight on Arvinas, Raises Price Target to $16
Barclays analyst Etzer Darout maintains Arvinas (NASDAQ:ARVN) with a Overweight and raises the price target from $15 to $16.
11-06 22:27
Arvinas Q3 EPS $(0.48) Beats $(0.81) Estimate, Sales $41.900M Beat $23.600M Estimate
Arvinas (NASDAQ:ARVN) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.81) by 40.96 percent. This is a 29.41 percent increase over losses of $(0.68) per share from the same
11-05 20:06
Earnings Scheduled For November 5, 2025
Companies Reporting Before The Bell • Avient (NYSE:AVNT) is estimated to report...
11-05 19:12
Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting
Arvinas宣布其 PROTAC BCL6 降解剂 ARV-393 与 glofitamab 联合用药的临床前数据将在2025年美国血液学会年会上以壁报形式展示。该研究详细介绍了 ARV-393 通过降解 BCL6 蛋白（B细胞淋巴瘤的关键驱动蛋白）的潜力，并已于I期临床试验中评估其治疗非霍奇金淋巴瘤的效果。会议将于12月6日至9日在佛罗里达州奥兰多举行。
11-03 21:00
Arvinas to Participate in Upcoming Investor Conferences
Arvinas, Inc., a clinical-stage biotechnology company focused on developing targeted protein degradation therapies, announced that its management will participate in two upcoming investor conferences: Guggenheim’s 2nd Annual Healthcare Innovation Conference on November 11 and Jefferies London Healthcare Conference on November 11. Both presentations will be available via live audio webcast. Arvinas is advancing its PROTAC platform to degrade disea...
11-03 12:00
